InCarda Therapeutics is currently conducting a Phase 2 clinical trial (INSTANT) in patients with symptomatic paroxysmal atrial fibrillation (PAF). For more information, please refer to the clinicaltrials.gov registration link below.
https://www.clinicaltrials.gov/ct2/show/NCT03539302?term=INSTANT&cond=Atrial+Fibrillation&rank=1...
A.A. Marum, et al. | International Journal of Cardiology 2018
We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects. Methods: Flecainide was delivered via intratracheal administration at...
May 23, 2018 - San Francisco, CA
At the SF Business Times Bay Area Biotech Forum, InCarda’s Dr. Grace Colon presented a company update to investors where she discussed the clinical challenges of Atrial Fibrillation and InCarda’s novel approach to treating it called, InRhythm (oral flecainide...
Belardinelli | Circulation 2017; 136:A16836
Oral and IV routes for delivery of flecainide (FLEC) for acute cardioversion of atrial fibrillation (AF) have drawbacks: high doses (150-300 mg) and 2- to 4- hours wait time for cardioversion with oral dosing and hospitalization for IV administration. Studies in...